Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
Titel:
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
Auteur:
Nakamura, Y. Namikawa, K. Yoshikawa, S. Kiniwa, Y. Maekawa, T. Yamasaki, O. Isei, T. Matsushita, S. Nomura, M. Nakai, Y. Fukushima, S. Saito, S. Takenouchi, T. Tanaka, R. Kato, H. Otsuka, A. Matsuya, T. Baba, N. Nagase, K. Inozume, T. Fujimoto, N. Kuwatsuka, Y. Onishi, M. Kaneko, T. Onuma, T. Umeda, Y. Ogata, D. Takahashi, A. Otsuka, M. Teramoto, Y. Yamazaki, N.